This article is more than 5 years old. Information may no longer be current.

Analysis of ANCHOR data shows efficacy across all subgroups

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — Analysis of ANCHOR data at 24 months showed visual and anatomical benefits in all subgroups that were studied, one surgeon said.

During Retina Subspecialty Day, Dr. Heier showed that ANCHOR results were stable over all sub-groups up to 24 months.

The data support the earlier positive results of the ANCHOR study that favored ranibizumab over photodynamic therapy (PDT) at all key outcomes, Jeffrey S. Heier, MD, said at the Retina Subspecialty Day preceding the annual American Academy of Ophthalmology meeting.

"I've never heard anyone question Lucentis' (ranibizumab, Genentech) efficacy," he said.

Dr. Heier pointed to "dramatic treatment results" in this "remarkably consistent therapy."

Compared to PDT, ranibizumab showed a better gain in vision and a threefold greater decline in leakage. The overall treatment benefits were seen across all age groups and lesion sizes, he said.

The ANCHOR study was a multicenter, double-masked, controlled phase 3 study that randomly assigned 423 patients to either verteporfin PDT plus monthly sham or sham verteporfin PDT plus monthly intravitreal ranibizumab, dosed at either 0.3 mg or 0.5 mg.

"Ranibizumab remains a consistent and highly effective treatment," Dr. Heier said.